Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH001 plus chemotherapy in resected pancreatic cancer
NCT07114666Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2029
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Open-label trial of PGV002 in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoints: Disease-Free Survival at 36 months, Disease-Free Survival Rate at 36 months and 2 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
PGV002
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07114666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114666.